Exploring the next generation of antibody–drug conjugates

Tumour heterogeneity and resistance to cancer therapies

Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395

Strategies and challenges for the next generation of antibody–drug conjugates

Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Prodrugs: design and clinical applications

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D.-M., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,681

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Junutula, J. R., Raab, H. E., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,388

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor Cells

Kučerová, L., Fekiačová, A., Udvorková, N., Malchárková, P., Blahová, V., Jochova, S., Kaľavská, K., Čierna, Z., & Mego, M. (2025) · Cells · doi:10.3390/cells14040287 · Cited by 6

Future Landscape of Anti-Claudin 18.2 Antibodies in Gastric Adenocarcinoma

Covert, W. M., & Rogers, J. E. (2025) · Antibodies · doi:10.3390/antib14010026 · Cited by 6

Advances in Antibody–Drug Conjugates for Endometrial Cancer

Tu, P., Li, G., Zou, W., Xu, C., & Wang, J. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0763 · Cited by 6

Triptolide-based cleavable antibody-drug conjugates for pancreatic cancer

Wang, H., Huangfu, S., Ding, W., Sun, Z., Wu, Y., Yu, X., Jiang, B., & Chen, H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117798 · Cited by 6

Hydrazone-based photocages for precise sub-organelle visualization and drug release

Wang, X., Zhou, J., Cheng, Y., Wu, H., Su, X., Wang, R., Xiao, K., Zhang, W., Chen, Z., Xu, B., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01561-8 · Cited by 6

Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy

Xi, M., Zhang, F., Zhu, J., Shen, H., Wu, C., Gao, X., Wu, Y., Wu, Y., Shen, R., & Xia, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118019 · Cited by 6

STING pathways and Sjögren’s syndrome: Exploration from mechanism to treatment

Ka, Y., Tan, T., Fan, Y.-H., Liu, W., Wang, A., Wang, W., Gesang, Y., Zhang, J., Yao, X., Lin, X., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1649046 · Cited by 7

Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment

Noorkhajavi, G., Banakholdi, A., Torabi, A., Zoghi, A., Iranijam, E., & Safarzadeh, E. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04039-8 · Cited by 6

A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway

Liu, X., Liu, J., Zhou, Y., Li, M., Wang, F., Jiang, G., Xiao, Y., Cui, W., Jiang, M., Gu, L., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08278-5 · Cited by 6

Multi-attribute methods in antibody-drug conjugate characterization and quality control: Opportunities, challenges, and regulatory outlook

Kumar, D., & Trivedi, N. (2026) · Journal of Chromatography A · doi:10.1016/j.chroma.2026.466711 · Cited by 6

Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma

Huang, J., Ojo, A., & Liaw, B. C.-H. (2026) · Current Oncology · doi:10.3390/curroncol33020103 · Cited by 6

Dual-payload small-molecule drug conjugates enable bystander anticancer activity with reduced nonspecific release

Chen, C., Pan, Y., Zhang, N., Yang, T., Shi, J., Ren, B., He, Y., & Zhang, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114695 · Cited by 6

Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer

Guo, H., Xu, Z., Li, K., Guo, C., Lin, F., Pu, Q., & Wang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1787148 · Cited by 7

Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology

Jafari, K. N., Chai, C., Kim, S., & Kaur, K. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030386 · Cited by 6

Challenges and Opportunities for Cleavable Linkers Used in Polymer–Drug Conjugates

Karimi, F., Locock, K. E. S., Chiefari, J., Williams, C. C., & Blackman, L. D. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c03661 · Cited by 6

Antibody-drug conjugates-related interstitial lung diseases: data mining of the FAERS database

Yu, Z., Zhu, H., & Liao, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2401025 · Cited by 6

Delivery of Monomethyl Auristatin F to the Tumor Microenvironment with Noninternalizing Fibroblast Activation Protein-Cleavable Small Molecule–Drug Conjugates Elicits Potent In Vivo Anticancer Activity

Bocci, M., Principi, L., Gilardoni, E., Neri, D., Cazzamalli, S., & Galbiati, A. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00503 · Cited by 6

Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells

Usama, M., Hsu, Y.-C., Safaei, M., Chen, C., Han, K. H., Ho, Y., Yamaguchi, H., Li, Y., Hung, M., Wong, C., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217453 · Cited by 7

Is ADC a rising star in solid tumor? An umbrella review of systematic reviews and meta-analyses

Wei, H., Zhang, Y., Lu, Y., Zou, Y., Zhou, L., Qin, X., & Jiang, Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-13726-8 · Cited by 6

Leveraging HER2-targeted biparatopic antibodies in solid tumors

Liu, X., Fan, X., Gao, X., Hu, W., & Sun, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107687 · Cited by 6

Light-induced chemistry for protein functionalisation

Berton, C., & Holland, J. P. (2025) · Chemical Communications · doi:10.1039/d4cc06529h · Cited by 6

TROP2-Directed Antibody-Drug Conjugates in Advanced Non–Small Cell Lung Cancer: A Fading Hope?

Pérol, M. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01043 · Cited by 6

DNA self-assembly-mediated high drug-antibody ratio ADC platform for targeted tumor therapy and imaging

Jin, S., Zhuang, X., Xu, Y., Nie, G., Chen, S., & Pan, L. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102459 · Cited by 6

Expanding the potential of antibody–drug conjugates in gastrointestinal malignancies: beyond HER2 targets

Ntellas, P., Athauda, A., Sugiyama, K., Le, M. L., Crespi, V., & Chau, I. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100154 · Cited by 5

IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia

Hui, L., Xiao, J., Zhao, Z., Zhang, J., Luan, H., Zhang, J., Sun, Y., Meng, X., Wang, H., Li, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016432 · Cited by 5

Development of Multivalent FAP-Targeted Small Molecule–Drug Conjugates with Tailored MMAE Release Kinetics

Bocci, M., Principi, L., Neri, D., Cazzamalli, S., Gilardoni, E., & Galbiati, A. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0026 · Cited by 5

The potential of antibody-drug conjugates in immunotherapy for non-small cell lung cancer: current progress and future

Lin, H., Ma, X., Zhu, X., & Zhong, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1630056 · Cited by 6

Surface Engineering of Natural Killer Cells with Lipid-Based Antibody Capture Platform for Targeted Chemoimmunotherapy

Lim, S. Y., Kim, Y., Kim, H. B., Han, S., Yun, J., Kim, H., Ha, S., Chae, S., Won, Y., & Lim, K. S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101285 · Cited by 5

Insight on photosensitivity of bispecific antibody-drug conjugates: ROS-mediated degradation and payload conjugation-induced structure alterations

Liu, F., Song, W., Jia, S., Wang, G., Zhang, X., Lyu, C., Xing, D., Qu, Y., Liu, B., Yu, R., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107374 · Cited by 5

Real-Time Bioconjugation Reaction Monitoring of Antibody–Drug Conjugates with Multiattribute High-Throughput Hydrophobic Interaction Chromatography

Cadang, L., Li, S., Wang, J., Stumpf, A. W., Kempen, T. J., Dai, L., Bouskila, A., Meadows, C. W., Breton, A., Yi, L., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c03553 · Cited by 5

Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions

Eltaib, L., Afzal, M., Maji, C., Malathi, H., Goyal, K., Ali, H., Gupta, G., & Hussain, M. S. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04848-8 · Cited by 5

Current landscape of sequencing ADCs in metastatic breast cancer

McLaughlin, S., Ravani, L. V., Moy, B., Medford, A. J., Isakoff, S. J., Liu, T., Ellisen, L. W., Spring, L. M., Wander, S. A., & Abelman, R. O. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251396656 · Cited by 6

Combining an anti-HER2 antibody-drug conjugate with an anti-nectin-4 antibody-drug conjugate enhances efficacy in breast cancer and gastric cancer models

Yazdi, N., Pourjamal, N., Li, H., Laakkonen, P., Joensuu, H., & Barok, M. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04246-x · Cited by 5

Ultrasound–triggered tumor‐selective nitric oxide release enhances tumor penetration of antibody–conjugated nanomedicine

Wang, X., Duan, R., Chen, X., Liu, T., & Liu, Z. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70117 · Cited by 5

Antibody–Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives

Xie, D., Yang, C. C.-K., Gao, S., Li, J., Yang, J., Li, X., Jiang, R., Cao, F., Zhang, S., Wang, L., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073287 · Cited by 5

Dual-Targeting Multivalent Aptamer-Drug Hybrids for Synergistic Cancer Immunotherapy

Chi, H., Du, Y., Lv, W., An, K., Lv, X., Zhao, S., Zeng, Y., Liu, X., Li, P., Qu, W., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c21968 · Cited by 5

Integrating antibody–drug conjugates, multispecific antibodies, targeted protein degradation and nanomedicine in precision oncology

Ali, I., Faiza, M. R., Mehmood, A. K., Wang, Z., Zhang, F., & Zhang, X. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2687011 · Cited by 4

From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine

Qiao, L., Wu, L., Xiao, Y., Qiu, J., Qiao, X., Dong, X., Lei, C., Wang, W., Zhao, Y., & Hua, Z. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01827-1 · Cited by 5

Development and applications of enzymatic peptide and protein ligation

Cui, Y., Han, D., Bai, X., & Shi, W.-W. (2024) · Journal of Peptide Science · doi:10.1002/psc.3657 · Cited by 5

A Brief Chronicle of Antibody Research and Technological Advances

Araki, K., & Maeda, R. (2024) · Antibodies · doi:10.3390/antib13040090 · Cited by 9

Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice?

Pagliari, G. G., Colonese, F., Canova, S., Abbate, M. I., Sala, L., Petrella, F., Clementi, T. D., & Cortinovis, D. L. (2024) · Cancers · doi:10.3390/cancers16233892 · Cited by 7

Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology

Sevilla-Carrillo, I., García-Tercero, E., Alonso‐Moreno, C., & Moya‐López, C. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206348204241128063329 · Cited by 5

Metallodrugs: From mere cytotoxic agents to immune modulators and checkpoint inhibitors

Nafees, M., Hanif, M., & Yang, P. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111013 · Cited by 5

Exploring therapeutic and diagnostic potential of cysteine cathepsin as targets for cancer therapy with nanomedicine

Giri, A., Hong, I., Kwon, T. K., Kang, J., Jeong, J., Kweon, S., & Yook, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144324 · Cited by 5

Introduction of Reactive Thiol Handles into Tyrosine-Tagged Proteins through Enzymatic Oxidative Coupling

Huang, P., Cao, W., Fetzer, J. L., Dolan, N. S., & Francis, M. B. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06195 · Cited by 6

Multicheckpoint Cellular Targeting of siRNAs Using Antibody-Directed Lipid-Polymer Hybrid Nanoparticles

Das, R., Medeiros, J., Krishna, J., Munugoti, S., Dutta, R., Devarajan, A., Ghosh, A., & Thayumanavan, S. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00205 · Cited by 5

Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker

Brylev, V. A., Ryabukhina, E. V., Nazarova, E. V., Samoylenkova, N. S., Gulyak, E. L., Sapozhnikova, K. A., Dzarieva, F., Ustinov, A. V., Pronin, I., Usachev, D. Y., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111434 · Cited by 5

Sequencing the monoclonal antibody variable regions using multiple charge integration middle-down strategy and ultraviolet photodissociation

Liu, Z., Liu, Z., Zhao, H., Xiao, C., Yang, X., & Wang, F. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.343450 · Cited by 5

Challenges and opportunities in single-domain antibody-based tumor immunotherapy

Xi, X., Guo, S., Gu, Y., Wang, X., & Wang, Q. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189284 · Cited by 5

Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis

Fang, W., Ma, X., & Liu, B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2472493 · Cited by 5

Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer

Wen, J., Cui, W., Yin, X., Chen, Y., Liu, A., Wang, Q., & Meng, X. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0470 · Cited by 5

Industrial Horizons in Pharmaceutical Science

Brader, M. L., Kim, H., Koo, O., Nagapudi, K., & Su, Y. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00544 · Cited by 5

Molecular Crosstalk and Therapeutic Synergy: Tyrosine Kinase Inhibitors and Cannabidiol in Oral Cancer Treatment

AlRaheem, Z. S. G., Le, T. T., Seyfoddin, A., & Li, Y. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080584 · Cited by 4

Structural Characterization of Linker Shielding in ADC Site-Specific Conjugates

Jaime-Garza, M., Waight, A. B., Hudlikar, M. S., Eddins, M. J., Rasti, E. S., Zaragoza, J. P. T., Fayadat‐Dilman, L., Chrencik, J., Gabelli, S. B., Chen, Y.-T., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121568 · Cited by 4

Clinical advances and challenges of antibody-mediated targeted drug delivery in breast cancer therapeutics

Rejili, M. (2026) · Discover Oncology · doi:10.1007/s12672-026-04492-5 · Cited by 4

Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody–Drug Conjugates Bearing DXd as a Cytotoxic Payload

Manabe, S., Senga, S., Iwamoto, S., Yarita, H., Takahashi, R., Mitani, A., Sumiyoshi, W., Hoshinoo, A., Hiranyakorn, M., Kinoshita, T., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c10898 · Cited by 4

The symbiotic axis between the acidic tumor microenvironment and cancer stem cells: a driver of malignancy and therapeutic resistance

汪正宇, Yuan, H., Liu, M., Yuan, J., & Chen, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1804379 · Cited by 5

Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches

Kidwai, N., Chen, M. F., Postow, M. A., Hassel, J. C., & Callahan, M. K. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432462 · Cited by 5

Engineering heavy chain antibody‐drug conjugates against solid tumors for a one‐shot kill

Liu, X., Ning, W., Wang, L., Liu, H., Zeng, H., Qin, X., Chen, Y., Chen, F., Xu, L., Zhao, Y., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12616 · Cited by 4

Immunotherapies in breast cancer: harnessing the cancer immunity cycle

Lok, V. M., Olson-Mcpeek, S. K., Spiegelhoff, G., Cortez, J., Detz, D., & Czerniecki, B. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2427038 · Cited by 4

The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma

Ahmed, G., Hamadani, M., & Al-Juhaishi, T. M. S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2453524 · Cited by 4

Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer

Shen, K., Yuan, S., Su, N., Tang, F., Rehim, S., Wang, H., Guo, H., Zhang, Y., Wu, Y., & Wang, H. (2025) · Oncology Reports · doi:10.3892/or.2025.8901 · Cited by 4

Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4

Qiao, Y., Zhao, W., Gou, Y., Li, Y., Su, F., Wang, R., Wang, J., Zhang, H., Sun, L., Qian, F., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2504776 · Cited by 4

Expanded ribosomal synthesis of non-standard cyclic backbones in vitro

Lee, K., Park, H., Devarapalli, R. K., Im, D., Seo, J., & Lee, J. (2025) · Nature Communications · doi:10.1038/s41467-025-60126-4 · Cited by 4

Surface keratin 1, a tumor-selective peptide target in human triple-negative breast cancer

Yao, S.-J., Amirrad, F., Ziaei, E., Saghaeidehkordi, A., Roosan, M. R., Shamloo, K., Sharma, A., Sumbria, R. K., Nauli, S. M., Bunick, C. G., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-05351-z · Cited by 4

Second Generation Tiancimycin-Based Antibody–Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies

Kiefer, A. F., Thirugnanasambantham, P., Jin, Y., Steele, A. D., Hwang, D., Jiang, Y., Adhikari, A., Yang, D. J., Chang, J., Tafesse, R., et al. (2025) · JACS Au · doi:10.1021/jacsau.5c00353 · Cited by 4

Developing angiogenesis-related prognostic biomarkers and therapeutic strategies in bladder cancer using deep learning and machine learning

Li, Y., Zuo, L., Song, X., Huang, Y., Zou, K., Dong, X., & Liu, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-08945-9 · Cited by 4

Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology

Shah, S. D., Jewell, R. C., Ferron‐Brady, G., & Visser, S. A. G. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-09988-1 · Cited by 4

Proximity-based site-specific labeling of a native IgG Fab fragment by a fusion microbial transglutaminase-protein G variant

Murozono, K., Nishioka, R., Kawaguchi, Y., Kimura, M., & Kamiya, N. (2025) · New Biotechnology · doi:10.1016/j.nbt.2025.08.004 · Cited by 5

Albubody: an engineered scFv variant platform for site-specific drug conjugation and enhanced tumor efficacy

Kwon, N. H., Lee, J. H., Kim, Y., Hahn, Y. S., & Kwon, I. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114165 · Cited by 4

The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer

Wooster, M. E., May, M. S., Agrawal, P., Lee, J., May, B. L., Ma, X., Bogdan, S., Shu, C. A., Henick, B. S., Saqi, A., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf236 · Cited by 4

Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors

Brea, E. J., Baldacci, S., Savage, N. J., Facchinetti, F., Hinchey, C., Chakravarti, S., Mottram, A., Ngo, K. H., Vo, H. V., Leeper, B. A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0527 · Cited by 4

Colloidal Stability Assessment of a Model Antibody Oligonucleotide Conjugate

Banks, D. D., & Cordia, J. F. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01126 · Cited by 4

Stoichiometric Antibody–Polymer–Drug Conjugate for Effective Low-Dose Treatment of Breast Cancer

Lehot, V., Lidický, O., Most, J., Nothisen, M., Erb, S., Dovgan, I., Osypenko, A., Koniev, O., Kolodych, S., Kotrchová, L., et al. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00598 · Cited by 4

Therapeutic efficacy of sacituzumab govitecan in recurrent refractory germ cell tumors

Udvorková, N., Blahová, V., Malchárková, P., Jochová, S., Kaľavská, K., Fekiačová, A., Pavel, J., Horák, S., Džongov, A., Janko, J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118659 · Cited by 4

Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate

Liang, Z., Xie, H., Mao, M., Hou, B., Wei, J. C., & Wu, D. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103497 · Cited by 4

Development and application of antibody-drug conjugates in gynecological cancers

Zheng, R., Zhang, J., Zhou, J., Zhang, Z., Niu, M., Jing, F., Wu, K., Yi, M., & Li, T. (2025) · Science China Life Sciences · doi:10.1007/s11427-025-3016-4 · Cited by 4

Advances in LC–MS strategies for comprehensive characterization and quantification of antibody-drug conjugates in preclinical and clinical settings

Kumar, D., & Trivedi, N. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.466606 · Cited by 6

Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue

Borremans, K., Pabba, A., Zels, G., Mahdami, A., Carette, C., Maetens, M., Baelen, K. V., Cauwenberge, J. V., Nguyen, H.-L., Izci, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67840-z · Cited by 4

Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy

Barainka, M., Zheleva, A., Pérez-Cervera, Á., Villanueva, H., Meraviglia-Crivelli, D., Moreno, B., & Pastor, F. (2026) · iScience · doi:10.1016/j.isci.2025.114597 · Cited by 4

A novel luteinizing hormone-releasing hormone (LHRH) receptor-targeting peptide LHRH-III': Design and application for targeted breast cancer therapy

Qiu, B., Fan, R., Si, G., Wang, J., Wang, K., Zheng, G., & Tian, X. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118563 · Cited by 4

Next-generation drug conjugates for breast cancer: Clinical prospects and mechanism-based strategies to overcome resistance

Zhao, M., Liu, W., Lu, W., Li, Z., & Wu, H. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104599 · Cited by 4

Rapid and selective characterization of antibody-drug conjugates in complex sample matrices by native affinity liquid chromatography-mass spectrometry

Kristensen, D. B., Eskesen, N. S., Coll-Satue, C., Nicolas, A., Simonsen, J. K., Rasmussen, L., Sloth, T. M., Ørgaard, M., Madzharova, E., Krabbe, S., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2618314 · Cited by 4

Application of nanomaterials in the treatment of diabetes and its complications: As nanocarriers or with inherent therapeutic functions

Ma, Y., Lan, Z., Zhong, L., Zhao, M., Luo, Y., Xiang, T., & Zhou, S. (2026) · Biomaterials Advances · doi:10.1016/j.bioadv.2026.214783 · Cited by 5

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer

Çetin, B., Erdem, D., Karaman, İ., & Gümüşay, Ö. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01391-3 · Cited by 4

Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming

Lu, N., Yan, B., Li, Y.-Q., & Wan, J.-L. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01799-2 · Cited by 4

Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions

Etessami, J. D., Valenza, C., Tolcher, A. W., LoRusso, P. M., & Curigliano, G. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517110 · Cited by 4

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer

Garitaonaindía, Y., Wakelee, H. A., Reck, M., Forde, P. M., Cascone, T., Spicer, J. D., & Provencio, M. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01174-7 · Cited by 5

Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management

Kovac, M. B., & Šeruga, B. (2024) · Radiology and Oncology · doi:10.2478/raon-2024-0027 · Cited by 4

Theranostics: Timing is Everything

Turner, J. H. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2024.0088 · Cited by 4

Diagnosis and Risk Stratification of Ovarian Mucinous Neoplasms: Pattern of Invasion, Immunohistochemistry, and Molecular Diagnostics

Köbel, M., Parra‐Herran, C., & Gorringe, K. L. (2024) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000473 · Cited by 4

LINC00870 promotes imatinib resistance in gastrointestinal stromal tumor via inhibiting PIGR glycosylation modifications

Li, Y., Dai, Z., Cheng, Z., He, J., Yin, Y.-R., Liu, X., Zhang, J., Hu, G., Chen, Y., Wang, X. J., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41934 · Cited by 4

An Affibody-Cytotoxin Conjugate-Based Nanoagent for EGFR Targeting and Precise Therapy of Epidermal Squamous Cell Carcinoma

Yang, X., Xia, X., Li, Q., Zhao, M., Gao, W., Xia, X., Huang, W., & Yan, D. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c06470 · Cited by 4

The Role of ETS2 in Macrophage Inflammation

Stankey, C. T., & Lee, J. C. (2025) · DNA and Cell Biology · doi:10.1089/dna.2025.0064 · Cited by 5

Development of antibody-drug conjugates in gastric cancer: an overview of clinical trials from 2005 to 2025

Duan, R. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002930 · Cited by 4

How antibody–drug conjugates aim to take down cancer

Plackett, B. (2024) · Nature · doi:10.1038/d41586-024-01426-5 · Cited by 4

Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody–Drug Conjugates

Ahangarpour, M., Brimble, M. A., & Kavianinia, I. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00199 · Cited by 4

Topological Scaffold‐Based Trispecific Recombinant Protein‐Drug Conjugates for Solid Tumor Eradication

Jiang, H., Yuan, Y., Zhang, X., Chen, W., Mao, H., Li, R., & Jiang, X. (2025) · Advanced Science · doi:10.1002/advs.202501093 · Cited by 3

Evolving bioanalytical strategies in the wake of pioneering biotherapeutics

Sirtori, F. R., Ianni, A. D., Crosasso, C., Bertotti, E., Molinaro, F., Salve, I. D., Barbero, L. M., & Cowan, K. J. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2546775 · Cited by 4

Immunotherapy for precision medicine in colorectal cancer

Cao, M., Xu, M. Y., Bairmani, Z. A., Bashir, B., Waldman, S. A., & Snook, A. E. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2560303 · Cited by 3

Next Generation Antibody–Drug Conjugates: Molecular Design Innovations And Overcoming Resistance – A Comprehensive Review

Hari Nandhini.A, D. S. S. M. B. R. (2025) · Vascular and Endovascular Review · doi:10.64149/j.ver.8.16s.217-224

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Metrangolo, V., & Engelholm, L. H. (2024) · Cancers · doi:10.3390/cancers16020447 · Cited by 77

Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs

Wu, D., Yang, K., He, R., Yin, R., & Shui, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1669592 · Cited by 25

Antibody-drug conjugates: mechanism, progress and future directions of cancer targeted therapy

Li, M., Wu, G., Chen, B., Zheng, Z., Ning, X., Li, J., De, Z., Li, J., & Song, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02817-0

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209